Pfizer Inc. and BioNTech SE submitted initial trial data for their COVID-19 vaccine in children aged 5 to 11 to U.S. regulators on Tuesday and said they would make a formal request for emergency use authorization in the coming weeks.
Pfizer-BioNTech submit data to U.S. FDA for COVID-19 vaccine in younger children
Post a Comment